Part One introduced what GLP-1s are and why so many people are reaching for them. Part Two is where we get honest about the harder questions — the ones that rarely come up in a ten-minute prescription appointment, and the ones that make the difference between short-term results and long-term health.
The Full Side Effect Picture
The gastrointestinal effects — nausea, diarrhea, constipation, vomiting, bloating — are the most widely reported and the ones most people have heard about. They are real, typically worst in the early weeks or when doses increase, and for most people they improve substantially with time and slow dose titration. But they are only one part of a more complex picture.
Figure 2: GLP-1 side effects span multiple organ systems — monitoring and nutrition support matter throughout treatment
Muscle and Lean Mass Loss
Research indicates that a significant proportion of weight lost on GLP-1 medications can come from lean muscle mass rather than fat alone. Muscle is not just about strength or appearance — it is your metabolic engine, supporting resting metabolism, blood sugar regulation, bone health, and resilience during illness. Losing substantial muscle during weight loss is not a neutral trade-off, and it directly increases the risk of weight regain once treatment changes.
The evidence-based response is a combination of adequate protein intake and consistent resistance exercise — both calibrated to your individual body by a gut health dietitian. Working with a dietitian from the first day of treatment is not optional. It is one of the most impactful decisions you can make.
Bone Density
When the body carries less weight, bones experience less mechanical load and can lose density over time — particularly at the hip. This risk is most significant for women over 50 and those with existing osteoporosis risk factors. Wegovy’s prescribing information now includes a specific warning about hip fracture risk. Weight-bearing and resistance exercise, alongside targeted nutritional guidance from a dietitian, are the primary protective strategies.
Mental Health — A Complex Picture
The mental health effects of GLP-1 medications are more complex than most prescribing conversations acknowledge. Many people experience genuine improvements — mood lifts as weight decreases, energy returns, self-confidence rebuilds. Research also suggests these drugs may reduce alcohol cravings and addictive behaviors through their action on the brain’s reward pathways — an exciting area of ongoing investigation.
However, pharmacovigilance databases have documented reports of depression, anxiety, and in rarer cases, suicidal ideation. One likely mechanism is neurochemical: GLP-1 drugs suppress dopamine-associated food reward, and for people with pre-existing mental health vulnerabilities, losing that reward pathway without adequate support can be destabilizing. Nutritional depletion — particularly of B vitamins and magnesium, which are critical for mood and cognitive function — can compound this effect when food intake drops significantly.
There is also a dimension that almost no clinical conversation acknowledges: for many people, food has served as a primary coping mechanism for stress, grief, or loneliness. When a GLP-1 medication removes the pull of that mechanism almost overnight, the emotional needs it served do not disappear — they surface differently. A dietitian who works with the whole person, not just nutrition numbers, can make an enormous difference here.
Gallbladder and Pancreatic Effects
GLP-1 medications reduce gallbladder contractions. Combined with the excess cholesterol released during rapid fat loss, this increases the risk of gallstones and bile duct issues — particularly with higher doses, longer use, or significant weight loss. Anyone with a history of gallbladder problems should be monitored carefully and discuss this risk with their prescribing doctor before starting treatment.
Regarding the pancreas: early reports raised concerns about pancreatitis and pancreatic cancer risk, but most large rigorous studies have not found a significant increase in these outcomes. Mild elevations in pancreatic enzymes can occur, but serious pancreatic events remain rare. Medical supervision and awareness of warning symptoms remain important.
Thyroid Cancer: What the Evidence Actually Shows
Animal studies — specifically in rodents — raised concerns about thyroid tumors in response to GLP-1 drugs. Human data remain mixed and inconclusive. A large Scandinavian study found no significantly increased thyroid cancer risk in GLP-1 users. However, a French cohort study reported a higher risk after one to three years of use. GLP-1 drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A full thyroid panel before starting treatment is a reasonable precaution for anyone with thyroid concerns.
Toxic Load from Rapid Fat Loss — An Underappreciated Concern
Fat tissue acts as a storage depot for fat-soluble pollutants and environmental toxins that accumulate over a lifetime. When fat breaks down quickly, these compounds are released into circulation — temporarily increasing the load on the liver, kidneys, and other detoxification pathways. If elimination is further impaired — for example by constipation, a common GLP-1 side effect — there is a theoretical risk that these compounds redistribute to other organs.
This is an area where the evidence is still developing, but the principle is sound: faster is not always better when it comes to fat loss. Gradual, well-supported weight loss — with adequate hydration, bowel regularity, and nutritional support — is safer and more sustainable than the most rapid possible reduction.
⚕️ Bottom line: Weight loss should ideally be gradual and supported by nutritional and lifestyle strategies that protect elimination pathways, preserve muscle, and nourish the gut microbiome. This is exactly the work of a gut health dietitian.
The Alzheimer’s Question
Large observational studies found that people with type 2 diabetes taking GLP-1 drugs developed dementia 40–70% less often than those on other diabetes medications. This led to the EVOKE and EVOKE+ Phase 3 clinical trials, enrolling 3,808 participants with early Alzheimer’s disease. Results presented in December 2025 showed semaglutide did not significantly slow cognitive decline compared to placebo. Some biomarker improvements were observed but did not translate to clinical benefit. The current evidence suggests GLP-1s may protect the brain indirectly through better metabolic control and reduced inflammation — but do not appear to treat established Alzheimer’s directly. Research continues.
Additional Side Effects Documented in the Literature
Beyond those covered above, the following have been reported across clinical studies and pharmacovigilance databases:
- Common: Headache, fatigue, dizziness, injection-site reactions, mild low blood sugar (primarily when combined with insulin or sulfonylureas).
- Gastrointestinal: Delayed gastric emptying (which can be problematic around surgery or anesthesia), gastroesophageal reflux, abdominal pain
- Renal: Dehydration and acute kidney injury, often secondary to vomiting or diarrhea — adequate hydration is essential.
- Cardiovascular: Mild increases in resting heart rate; rare arrhythmias documented in some reports.
- Reproductive: Tirzepatide may reduce the effectiveness of oral contraceptives — barrier methods are recommended for four weeks after initiation and each dose increase.
- Neurological: Rare reports of altered taste and mild cognitive complaints.
- Immunological: Rare hypersensitivity reactions.
Before Starting: Why a Baseline Assessment Matters
Because GLP-1 medications interact with so many organ systems, a baseline health assessment before starting can identify who carries higher risk for specific side effects and allow precautions to be put in place. This includes gallbladder and liver markers, pancreatic enzymes, a thyroid panel, a lipid profile, and nutrient status — particularly B12, vitamin D, iron, magnesium, and calcium. A gut health dietitian can work alongside your medical team to monitor nutritional status throughout treatment, catching deficiencies early, adjusting food strategies, and making sure your body is supported at every stage.
The Drop in Bariatric Surgery — and What GLP-1s Can and Can’t Do
One of the clearest signals of GLP-1s’ cultural impact: bariatric surgeries in the US fell nearly 42% between 2019 and 2024, as patients and physicians turned toward medications. Understanding how these approaches compare — not to declare a winner, but to make genuinely informed decisions — matters.
Figure 3: Both approaches can work; the right choice is individualised and always most effective with dietitian support from day one
A 2025 real-world head-to-head study from NYU Langone Health found patients who had bariatric surgery lost approximately 24% of body weight over two years, versus 4.7–12% for GLP-1 patients depending on adherence duration. Surgery consistently achieves more weight loss — but it permanently alters the gastrointestinal tract, requiring lifelong nutritional supplements. Long-term studies show that iron, B12, and folate deficiencies increase significantly over 10 years post-surgery, even in patients who actively supplement. By five years after surgery, fewer than 30% of patients are receiving adequate clinical follow-up.
GLP-1 medications carry none of these permanent anatomical changes. Their side effects are reversible. And with a dietitian’s support, the nutritional risks can be substantially managed through food-first strategies without the complexity of permanent post-surgical malabsorption.
However, bariatric surgery permanently alters the gastrointestinal tract, creating lifelong nutritional requirements. Surgical complications including leaks, strictures, dumping syndrome, bowel obstruction, and bacterial overgrowth are documented clinical realities requiring lifelong vigilance.
Importantly, these approaches are not always in competition. GLP-1 medications can also help post-bariatric surgery patients who experience weight regain — supporting continued metabolic management years after surgery.
⚕️ Bottom line: Pairing GLP-1 medications with professional nutrition support from a dietitian may improve long-term outcomes for both GLP-1 users and post-bariatric patients — reducing the risk of nutritional deficiencies, muscle loss, and weight regain.
The Weight Rebound Reality — and Why It’s Not Your Fault
Here is the question people are most afraid to ask: what happens if I have to stop?
The clinical answer is sobering. Research shows that many people who discontinue GLP-1 therapy begin regaining weight within weeks — some studies project a return toward original weight within approximately two years of stopping, at roughly a pound per month on average. The underlying biology reasserts itself: the disrupted appetite signaling, the altered gut hormones, the metabolic dysfunction that characterizes obesity as a chronic disease does not disappear because the medication does.
This is not a failure of the person. It is the biology resuming.
The emotional weight of this reality is not small. Many people have fought for years — sometimes their entire adult lives — to lose weight. They have sacrificed joy, money, and mental health to diets that didn’t work. When a GLP-1 medication finally quiets the hunger, the relief is profound. The thought of losing that — of watching months of hard-won change slowly reverse — is genuinely devastating.
This is precisely why having a gut health dietitian in your care team from day one matters not as an add-on, but as a foundation. The gut microbiome you rebuild with professional support, the dietary patterns you establish, the muscle mass you protect, the inflammation you reduce through targeted nutrition — these are real biological assets that remain with you. They cannot fully replace what the medication does, but they meaningfully slow the return of weight, protect metabolic health, and support your body through whatever changes lie ahead.
⚕️ Bottom line: GLP-1 medications are increasingly understood as long-term treatments for a chronic disease — not a finite course. Nutrition support from a dietitian builds the biological and behavioural foundation that matters whether you stay on the medication, taper the dose, or eventually need to stop.
You now know how these drugs work, what they risk, and why the support around them matters as much as the prescription itself. But GLP-1s are not just a medical story. They have detonated inside culture — reshaping bodies on red carpets, igniting debates about who deserves access, and forcing an uncomfortable reckoning with the way our society has always talked about weight, food, and worth. In Part Three, we go there.
Want to build a foundation that supports you — on GLP-1s or off?
References
Exploring the side effects of GLP-1 receptor agonists: to ensure its optimal positioning. PMC. 2025. doi:10.1371/journal.pmed.1004321
Neuropsychiatric adverse events associated with GLP-1 receptor agonists: a pharmacovigilance analysis. EClinicalMedicine. 2025. doi:10.1016/j.eclinm.2024.102918
Bezin J, Gouverneur A, et al. GLP-1 receptor agonists and risk of thyroid cancer. Diabetes Care. 2023;46(2):384-390. doi:10.2337/dc22-1148
Cheng HW, Yang SF, et al. Impact of GLP-1 receptor agonists on dementia incidence. Diabetes Metab Res Rev. 2025;41(5):e70058. doi:10.1002/dmrr.70058
Novo Nordisk. EVOKE and EVOKE+ Phase 3 results. Presented at: CTAD Conference; December 1–4, 2025; San Diego, CA.
Heindel JJ, Blumberg B, et al. Metabolism disrupting chemicals and metabolic disorders. Reprod Toxicol. 2017;68:3-33. doi:10.1016/j.reprotox.2016.10.001
Brown A, et al. Bariatric surgery vs GLP-1: head-to-head comparison. ASMBS Annual Scientific Meeting; June 17, 2025; Washington, DC.
Khanam M, et al. Comparative effectiveness of bariatric surgery vs GLP-1 receptor agonists. Cureus. 2024;16(9):e70068. doi:10.7759/cureus.70068
Humięcka M, et al. Prevalence of nutrient deficiencies following bariatric surgery. Nutrients. 2025;17(16):2599. doi:10.3390/nu17162599
Harvard Health Publishing. GLP-1 drugs versus bariatric surgery. January 2026. Accessed May 4, 2026. https://www.health.harvard.edu/weight-loss/glp-1-drugs-versus-bariatric-surgery